{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dysmyelopoietic+Syndromes&page=14",
    "query": {
      "condition": "Dysmyelopoietic Syndromes",
      "page": 14
    },
    "page_size": 10
  },
  "pagination": {
    "page": 14,
    "page_size": 10,
    "total_count": 1780,
    "total_pages": 178,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dysmyelopoietic+Syndromes&page=15&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dysmyelopoietic+Syndromes&page=13&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T06:44:19.802Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02923986",
      "title": "Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Chronic Myelogenous Leukemia, Ph1-Positive",
        "Acute Myeloid Leukemia",
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "BP1001 (varying dose)",
          "type": "DRUG"
        },
        {
          "name": "BP1001 (fixed dose)",
          "type": "DRUG"
        },
        {
          "name": "Dasatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bio-Path Holdings, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2017-09-01",
      "completion_date": "2020-05-27",
      "has_results": false,
      "last_update_posted_date": "2020-05-28",
      "last_synced_at": "2026-10-15T06:44:19.802Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02923986"
    },
    {
      "nct_id": "NCT03399773",
      "title": "Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Biphenotypic Leukemia",
        "Acute Lymphoblastic Leukemia",
        "Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
        "Hematopoietic and Lymphoid Cell Neoplasm",
        "Myelodysplastic Syndrome",
        "Myelodysplastic Syndrome With Excess Blasts"
      ],
      "interventions": [
        {
          "name": "Dilanubicel",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Thiotepa",
          "type": "DRUG"
        },
        {
          "name": "Total-Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Umbilical Cord Blood Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Aspirate",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Multigated Acquisition Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Electrocardiography",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "RADIATION",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "10 Years to 65 Years"
      },
      "enrollment_count": 31,
      "start_date": "2022-05-10",
      "completion_date": "2027-04-02",
      "has_results": true,
      "last_update_posted_date": "2026-07-10",
      "last_synced_at": "2026-10-15T06:44:19.802Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03399773"
    },
    {
      "nct_id": "NCT01465386",
      "title": "Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome",
        "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)",
        "Adult Acute Myeloblastic Leukemia Without Maturation (M1)",
        "Adult Acute Myeloid Leukemia in Remission",
        "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities",
        "Adult Acute Myeloid Leukemia With Del(5q)",
        "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)",
        "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)",
        "Adult Acute Promyelocytic Leukemia (M3)",
        "Adult Erythroleukemia (M6a)",
        "Adult Pure Erythroid Leukemia (M6b)",
        "Secondary Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "bortezomib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2011-11",
      "completion_date": "2015-03-02",
      "has_results": true,
      "last_update_posted_date": "2017-04-04",
      "last_synced_at": "2026-10-15T06:44:19.802Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01465386"
    },
    {
      "nct_id": "NCT04047641",
      "title": "Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Blasts 20 Percent or More of Bone Marrow Nucleated Cells",
        "High Risk Myelodysplastic Syndrome",
        "Recurrent Acute Biphenotypic Leukemia",
        "Recurrent Acute Myeloid Leukemia",
        "Recurrent High Risk Myelodysplastic Syndrome",
        "Refractory Acute Myeloid Leukemia",
        "Refractory High Risk Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Cladribine",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Idarubicin",
          "type": "DRUG"
        },
        {
          "name": "Quizartinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2019-10-22",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-12",
      "last_synced_at": "2026-10-15T06:44:19.802Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04047641"
    },
    {
      "nct_id": "NCT06577441",
      "title": "Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Aspiration",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Decitabine and Cedazuridine",
          "type": "DRUG"
        },
        {
          "name": "Enasidenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2025-06-12",
      "completion_date": "2027-03-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-06",
      "last_synced_at": "2026-10-15T06:44:19.802Z",
      "location_count": 145,
      "location_summary": "Berkeley, California • Irvine, California • Orange, California + 120 more",
      "locations": [
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Mateo",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06577441"
    },
    {
      "nct_id": "NCT07228624",
      "title": "Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myelodysplastic/Myeloproliferative Neoplasm",
        "Primary Myelofibrosis",
        "Secondary Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        },
        {
          "name": "Allogeneic Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "JAK Inhibitor",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Aspiration",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 50,
      "start_date": "2026-02-04",
      "completion_date": "2030-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-19",
      "last_synced_at": "2026-10-15T06:44:19.802Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07228624"
    },
    {
      "nct_id": "NCT01110473",
      "title": "ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia",
        "Acute Myelogenous Leukemia",
        "B-cell Chronic Lymphocytic Leukemia",
        "Chronic Myelogenous Leukemia",
        "Myelodysplasia"
      ],
      "interventions": [
        {
          "name": "ABT-348",
          "type": "DRUG"
        },
        {
          "name": "ABT-348 and azacitidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie (prior sponsor, Abbott)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 52,
      "start_date": "2010-04",
      "completion_date": "2013-06",
      "has_results": false,
      "last_update_posted_date": "2017-11-20",
      "last_synced_at": "2026-10-15T06:44:19.802Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • Atlanta, Georgia • Houston, Texas",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01110473"
    },
    {
      "nct_id": "NCT01930162",
      "title": "Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Single Umbilical Cord Blood Transplantation",
        "Non-myeloablative Conditioning",
        "Acute Lymphocytic Leukemia",
        "Myelodysplastic Syndrome",
        "Non-Hodgkin's Lymphoma",
        "Multiple Myeloma",
        "Chronic Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "HSC835",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 9,
      "start_date": "2014-10-07",
      "completion_date": "2016-08-29",
      "has_results": true,
      "last_update_posted_date": "2021-01-05",
      "last_synced_at": "2026-10-15T06:44:19.802Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01930162"
    },
    {
      "nct_id": "NCT00039923",
      "title": "Transfer of GPI-Linked Proteins to Transfused Patients With Paroxysmal Nocturnal Hemoglobinuria",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Paroxysmal Hemoglobinuria"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 7,
      "start_date": "2002-06",
      "completion_date": "2005-06",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-10-15T06:44:19.802Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00039923"
    },
    {
      "nct_id": "NCT04402541",
      "title": "Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia, in Relapse",
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "CB-5339",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cleave Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2020-06-08",
      "completion_date": "2023-07-23",
      "has_results": false,
      "last_update_posted_date": "2023-08-31",
      "last_synced_at": "2026-10-15T06:44:19.802Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • Fairway, Kansas • New York, New York + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Fairway",
          "state": "Kansas"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Greenville",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04402541"
    }
  ]
}